CA2373239A1 - Stability, biocompatibility optimized adjuvant (sba) for enhancing humoral and cellular immune response - Google Patents

Stability, biocompatibility optimized adjuvant (sba) for enhancing humoral and cellular immune response Download PDF

Info

Publication number
CA2373239A1
CA2373239A1 CA002373239A CA2373239A CA2373239A1 CA 2373239 A1 CA2373239 A1 CA 2373239A1 CA 002373239 A CA002373239 A CA 002373239A CA 2373239 A CA2373239 A CA 2373239A CA 2373239 A1 CA2373239 A1 CA 2373239A1
Authority
CA
Canada
Prior art keywords
sba
agent according
particles
oil
adjuvant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002373239A
Other languages
English (en)
French (fr)
Inventor
Rainer Helmut Muller
Nikolaus Grubhofer
Carsten Olbrich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmasol GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2373239A1 publication Critical patent/CA2373239A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CA002373239A 1999-05-20 2000-05-19 Stability, biocompatibility optimized adjuvant (sba) for enhancing humoral and cellular immune response Abandoned CA2373239A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19923256.3 1999-05-20
DE19923256 1999-05-20
PCT/EP2000/004565 WO2000071154A2 (de) 1999-05-20 2000-05-19 Stabilitäts-, biokompatibilitäts-optimiertes adjuvans (sba) zur erhöhung der humoralen und zellulären immunantwort

Publications (1)

Publication Number Publication Date
CA2373239A1 true CA2373239A1 (en) 2000-11-30

Family

ID=7908697

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002373239A Abandoned CA2373239A1 (en) 1999-05-20 2000-05-19 Stability, biocompatibility optimized adjuvant (sba) for enhancing humoral and cellular immune response

Country Status (11)

Country Link
EP (1) EP1183045A2 (tr)
JP (1) JP2003500365A (tr)
KR (1) KR20020012221A (tr)
AU (2) AU5214200A (tr)
BR (1) BR0010823A (tr)
CA (1) CA2373239A1 (tr)
DE (1) DE10024788A1 (tr)
MX (1) MXPA01011660A (tr)
TR (1) TR200103333T2 (tr)
WO (2) WO2000071154A2 (tr)
ZA (1) ZA200109147B (tr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10024788A1 (de) * 1999-05-20 2000-11-23 Gerbu Gmbh Stabilitäts-, Biokompatibilitäts-optimiertes Adjuvans (SBA) zur Erhöhung der humoralen und zellulären Immunantwort
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
ES2300568T3 (es) 2002-03-20 2008-06-16 Mannkind Corporation Aparato de inhalacion.
ES2379267T3 (es) * 2003-10-23 2012-04-24 Novartis Vaccines And Diagnostics, Inc. Composiciones estabilizadas
FR2873386B1 (fr) 2004-07-22 2011-01-14 Agence Francaise De Securite Sanitaire Des Aliments Afssa Composition vaccinale contre le rhodococcus equi
CA2575692C (en) 2004-08-20 2014-10-14 Mannkind Corporation Catalysis of diketopiperazine synthesis
KR20130066695A (ko) 2004-08-23 2013-06-20 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
CN104324362B (zh) 2005-09-14 2018-04-24 曼金德公司 以提高活性试剂对结晶微粒表面的亲和力为基础的药物配制方法
MX2008010721A (es) 2006-02-22 2008-09-01 Mannkind Corp Un metodo para mejorar las propiedades farmaceuticas de microparticulas que contienen dicetopiperazina y un agente activo.
US8424518B2 (en) 2008-06-13 2013-04-23 Mannkind Corporation Dry powder inhaler and system for drug delivery
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
EP2609954B1 (en) 2008-06-20 2021-12-29 MannKind Corporation An interactive apparatus for real-time profiling of inhalation efforts
TWI494123B (zh) 2008-08-11 2015-08-01 Mannkind Corp 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
JP5667095B2 (ja) 2009-03-11 2015-02-12 マンカインド コーポレイション 吸入器の抵抗を測定するための装置、システムおよび方法
KR20180036807A (ko) 2009-06-12 2018-04-09 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
WO2011056889A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
CA2801936C (en) 2010-06-21 2021-06-01 Mannkind Corporation Dry powder drug delivery system and methods
CN103826988B (zh) 2011-04-01 2016-03-09 曼金德公司 用于药物药盒的泡罩包装
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
AU2012328885B2 (en) 2011-10-24 2017-08-31 Mannkind Corporation Methods and compositions for treating pain
AU2013256565B2 (en) 2012-04-30 2015-12-03 Ossur Hf Prosthetic device, system and method for increasing vacuum attachment
AU2013289957B2 (en) 2012-07-12 2017-02-23 Mannkind Corporation Dry powder drug delivery systems and methods
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
CA2906817C (en) 2013-03-15 2022-01-18 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
MX2016000739A (es) 2013-07-18 2017-04-06 Mannkind Corp Composiciones farmacéuticas en polvo seco estables al calor y métodos.
CA2920488C (en) 2013-08-05 2022-04-26 Mannkind Corporation Insufflation apparatus and methods
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
US20180318415A1 (en) * 2015-12-08 2018-11-08 Glaxosmithkline Biologicals, Sa Novel adjuvant formulations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19745950A1 (de) * 1997-10-17 1999-04-22 Dds Drug Delivery Service Ges Arzneistoffträgerpartikel für die gewebespezifische Arzneistoffapplikation
WO2000006120A1 (en) * 1998-07-31 2000-02-10 Korea Institute Of Science And Technology Lipid emulsion and solid lipid nanoparticle as a gene or drug carrier
DE10024788A1 (de) * 1999-05-20 2000-11-23 Gerbu Gmbh Stabilitäts-, Biokompatibilitäts-optimiertes Adjuvans (SBA) zur Erhöhung der humoralen und zellulären Immunantwort

Also Published As

Publication number Publication date
ZA200109147B (en) 2002-05-08
AU5214200A (en) 2000-12-12
BR0010823A (pt) 2002-03-05
AU5809100A (en) 2000-12-12
EP1183045A2 (de) 2002-03-06
KR20020012221A (ko) 2002-02-15
WO2000071154A2 (de) 2000-11-30
WO2000071154A3 (de) 2001-06-28
DE10024788A1 (de) 2000-11-23
TR200103333T2 (tr) 2002-04-22
WO2000071077A2 (en) 2000-11-30
MXPA01011660A (es) 2004-04-05
JP2003500365A (ja) 2003-01-07

Similar Documents

Publication Publication Date Title
CA2373239A1 (en) Stability, biocompatibility optimized adjuvant (sba) for enhancing humoral and cellular immune response
JP6625587B2 (ja) Ｔｌｒ２を活性化するか、またはその活性を増加させるアジュバントを含むリポソーム組成物およびその使用
Mohanan et al. Administration routes affect the quality of immune responses: a cross-sectional evaluation of particulate antigen-delivery systems
EP1574210B1 (en) Microemulsions with adsorbed macromolecules
CN1980638B (zh) 用糖脂稳定基于脂质的佐剂制剂的组合物和方法
US8277823B2 (en) Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids
CN100384473C (zh) 油佐剂疫苗
US20200405846A1 (en) Emulsion adjuvant for intramuscular, intradermal and subcutaneous administration
Kallerup et al. Influence of trehalose 6, 6′-diester (TDX) chain length on the physicochemical and immunopotentiating properties of DDA/TDX liposomes
JP7409594B2 (ja) 医薬組成物、規定のサイズの脂質ベシクル粒子を使用する調製物のための方法、及びそれらの使用
CA2672338C (en) Archaeal polar lipid aggregates for administration to animals
CN103784953A (zh) 作为疫苗佐剂的水包油型亚微乳及其制备方法
Perrie et al. Recent developments in particulate-based vaccines
CN104043119A (zh) 一种新型疫苗佐剂及其制备方法
Myschik et al. Immunostimulatory lipid implants containing Quil-A and DC-cholesterol
AU744308B2 (en) Antigen vectors in the form of multilamellar vesicles
US20100209452A1 (en) Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
Ariaee et al. Mucosal adjuvant potential of Quillaja saponins and cross-linked dextran microspheres, co-administered with liposomes encapsulated with tetanus toxoid
JP2019202957A (ja) 免疫組成物
CN111166890A (zh) 一种缓释疫苗载体及其制备方法
WO2011138050A1 (en) Method for vaccination
US20220000779A1 (en) Immunogenic compositions
Turánek et al. Functionalised nanoliposomes for construction of recombinant vaccines: lyme disease as an example
Wilkhu et al. Developing Bilayer-Based Delivery Systems for Oral Delivery of Subunit Vaccines
Christensen et al. Liposomes in adjuvant systems for parenteral delivery of vaccines

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20060519